NCT05789056View on ClinicalTrials.gov

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Netherton Syndrome
Interventions
DRUG

QRX003, 4% Lotion

QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

Trial Locations (4)

46250

RECRUITING

Site #4, Indianapolis

72218

NOT_YET_RECRUITING

Site #2, San Antonio

92123

RECRUITING

Site #1, San Diego

02169

RECRUITING

Site #5, Quincy

Sponsors
All Listed Sponsors
lead

Quoin Pharmaceuticals

INDUSTRY

NCT05789056 - Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome | Biotech Hunter | Biotech Hunter